KLRS
NASDAQ · Biotechnology
Kalaris Therapeutics Inc
$6.00
+0.23 (+3.99%)
Financial Highlights (FY 2025)
Revenue
21.76M
Net Income
3.46M
Gross Margin
46.1%
Profit Margin
15.9%
Rev Growth
+16.8%
D/E Ratio
0.77
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 46.1% | 46.1% | 46.1% |
| Operating Margin | 17.7% | 21.0% | 20.2% |
| Profit Margin | 15.9% | 11.9% | 14.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Gross Profit | 10.04M | 9.45M | 9.50M |
| Operating Income | 3.86M | 4.29M | 4.16M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Gross Margin | 46.1% | 46.1% | 46.1% |
| Operating Margin | 17.7% | 21.0% | 20.2% |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| Rev Growth | +16.8% | +12.7% | +4.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 57.89M | 48.02M | 48.60M |
| Total Equity | 75.24M | 68.16M | 76.24M |
| D/E Ratio | 0.77 | 0.70 | 0.64 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |